vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $30.3M, roughly 1.3× SYPRIS SOLUTIONS INC). SYPRIS SOLUTIONS INC runs the higher net margin — -12.9% vs -161.8%, a 148.9% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -9.5%). SYPRIS SOLUTIONS INC produced more free cash flow last quarter ($-1.5M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
IBRX vs SYPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $30.3M |
| Net Profit | $-61.9M | $-3.9M |
| Gross Margin | 99.0% | 4.6% |
| Operating Margin | -169.0% | -10.9% |
| Net Margin | -161.8% | -12.9% |
| Revenue YoY | 407.0% | -9.5% |
| Net Profit YoY | -4.7% | -2992.6% |
| EPS (diluted) | $-0.06 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $30.3M | ||
| Q3 25 | $32.1M | $28.7M | ||
| Q2 25 | $26.4M | $31.4M | ||
| Q1 25 | $16.5M | $29.5M | ||
| Q4 24 | $7.6M | $33.4M | ||
| Q3 24 | $6.1M | $35.7M | ||
| Q2 24 | — | $35.5M | ||
| Q1 24 | — | $35.6M |
| Q4 25 | $-61.9M | $-3.9M | ||
| Q3 25 | $-67.3M | $517.0K | ||
| Q2 25 | $-92.6M | $-2.1M | ||
| Q1 25 | $-129.6M | $-899.0K | ||
| Q4 24 | $-59.2M | $135.0K | ||
| Q3 24 | $-85.7M | $390.0K | ||
| Q2 24 | — | $16.0K | ||
| Q1 24 | — | $-2.2M |
| Q4 25 | 99.0% | 4.6% | ||
| Q3 25 | 99.4% | 7.2% | ||
| Q2 25 | 99.5% | 8.2% | ||
| Q1 25 | 99.6% | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | -169.0% | -10.9% | ||
| Q3 25 | -173.5% | -6.1% | ||
| Q2 25 | -269.8% | -4.6% | ||
| Q1 25 | -390.1% | -0.4% | ||
| Q4 24 | -919.0% | 3.9% | ||
| Q3 24 | -1314.3% | 4.8% | ||
| Q2 24 | — | 3.6% | ||
| Q1 24 | — | -3.9% |
| Q4 25 | -161.8% | -12.9% | ||
| Q3 25 | -209.8% | 1.8% | ||
| Q2 25 | -350.3% | -6.5% | ||
| Q1 25 | -784.9% | -3.0% | ||
| Q4 24 | -783.4% | 0.4% | ||
| Q3 24 | -1404.0% | 1.1% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | -6.2% |
| Q4 25 | $-0.06 | $-0.17 | ||
| Q3 25 | $-0.07 | $0.02 | ||
| Q2 25 | $-0.10 | $-0.09 | ||
| Q1 25 | $-0.15 | $-0.04 | ||
| Q4 24 | $-0.08 | $0.00 | ||
| Q3 24 | $-0.14 | $0.02 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $17.8M |
| Total Assets | $501.9M | $107.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | — | ||
| Q3 25 | $257.8M | — | ||
| Q2 25 | $153.7M | — | ||
| Q1 25 | $61.6M | — | ||
| Q4 24 | $149.8M | — | ||
| Q3 24 | $130.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-500.5M | $17.8M | ||
| Q3 25 | $-524.3M | $20.0M | ||
| Q2 25 | $-570.7M | $18.7M | ||
| Q1 25 | $-591.4M | $19.0M | ||
| Q4 24 | $-489.1M | $19.6M | ||
| Q3 24 | $-745.1M | $18.2M | ||
| Q2 24 | — | $19.0M | ||
| Q1 24 | — | $20.8M |
| Q4 25 | $501.9M | $107.8M | ||
| Q3 25 | $519.0M | $112.5M | ||
| Q2 25 | $402.1M | $105.8M | ||
| Q1 25 | $303.8M | $110.2M | ||
| Q4 24 | $382.9M | $119.4M | ||
| Q3 24 | $364.6M | $121.6M | ||
| Q2 24 | — | $124.2M | ||
| Q1 24 | — | $129.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $-1.1M |
| Free Cash FlowOCF − Capex | $-71.3M | $-1.5M |
| FCF MarginFCF / Revenue | -186.2% | -5.0% |
| Capex IntensityCapex / Revenue | 2.4% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $-1.1M | ||
| Q3 25 | $-68.9M | $-178.0K | ||
| Q2 25 | $-79.7M | $1.1M | ||
| Q1 25 | $-85.9M | $-5.5M | ||
| Q4 24 | $-85.1M | $2.3M | ||
| Q3 24 | $-98.8M | $-4.8M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | $-71.3M | $-1.5M | ||
| Q3 25 | $-69.6M | $-390.0K | ||
| Q2 25 | $-80.8M | $941.0K | ||
| Q1 25 | $-87.0M | $-5.5M | ||
| Q4 24 | $-87.3M | $1.9M | ||
| Q3 24 | $-101.6M | $-4.9M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | -186.2% | -5.0% | ||
| Q3 25 | -217.2% | -1.4% | ||
| Q2 25 | -305.9% | 3.0% | ||
| Q1 25 | -526.9% | -18.8% | ||
| Q4 24 | -1155.4% | 5.7% | ||
| Q3 24 | -1663.2% | -13.8% | ||
| Q2 24 | — | 16.8% | ||
| Q1 24 | — | -5.7% |
| Q4 25 | 2.4% | 1.3% | ||
| Q3 25 | 2.3% | 0.7% | ||
| Q2 25 | 4.1% | 0.5% | ||
| Q1 25 | 6.8% | 0.0% | ||
| Q4 24 | 28.0% | 1.2% | ||
| Q3 24 | 45.7% | 0.4% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IBRX
Segment breakdown not available.
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
